HL 10

Drug Profile

HL 10

Latest Information Update: 15 Jun 2004

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Erasmus University; Friedrich-Alexander-University Erlangen-Nuremberg; HALAS Pharma
  • Developer LEO Pharma
  • Class Phospholipids; Pulmonary surfactants
  • Mechanism of Action Cell membrane permeability enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute lung injury

Highest Development Phases

  • Discontinued Acute lung injury; Adult respiratory distress syndrome

Most Recent Events

  • 08 Jun 2004 Discontinued - Phase-III for Acute lung injury in European Union (Intratracheal)
  • 08 Jun 2004 Discontinued - Phase-III for Adult respiratory distress syndrome in European Union (Intratracheal)
  • 13 May 2003 LEO Pharma is seeking a partner for the marketing of HL 10 in the USA and Japan (http://www.leo-pharma.com)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top